Trial
NCT01170650
Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED)
Phase IIITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Endocyte
Collaborators
—
Condition
Ovarian Cancer
Intervention
EC145
Why stopped
DSMB decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-09-30